All Stories

  1. Pre‐Posterior Distributions in Drug Development and Their Properties
  2. On implementing J effreys' substitution likelihood for B ayesian inference concerning the medians of unknown distributions
  3. Hybrid Frequentist/Bayesian Power and Bayesian Power in Planning Clinical Trials
  4. Optimising the trade‐off between type I and II error rates in the Bayesian context
  5. How to design a dose-finding study using the continual reassessment method
  6. Minimizing Patient Burden Through the Use of Historical Subject-Level Data in Innovative Confirmatory Clinical Trials
  7. Justify your alpha
  8. Statistical issues in first-in-human studies on BIA 10-2474: Neglected comparison of protocol against practice
  9. Response-adaptive clinical trials: case studies in the medical literature
  10. Simulation-based sample-sizing and power calculations in logistic regression with partial prior information
  11. The predictive distribution of the residual variability in the linear-fixed effects model for clinical cross-over trials
  12. Idle thoughts of a ‘well-calibrated’ Bayesian in clinical drug development
  13. How to test hypotheses if you must
  14. Limitations of within-person study designs
  15. Medical Statistics
  16. Fracture risk with use of liver enzyme inducing antiepileptic drugs in people with active epilepsy: Cohort study using the General Practice Research Database
  17. Advancing clinical trial design in pulmonary hypertension
  18. A dual-centre, cohort comparison of open, laparoscopic and robotic-assisted radical cystectomy
  19. Within-person study designs had lower precision and greater susceptibility to bias because of trends in exposure than cohort and nested case–control designs
  20. Source Data Verification by Statistical Sampling: Issues in Implementation
  21. Cutaneous lymphocyte antigen and α4β7 T-lymphocyte responses are associated with peanut allergy and tolerance in children
  22. Discussions
  23. Estimates of Outcomes Up to Ten Years after Stroke: Analysis from the Prospective South London Stroke Register
  24. Short Term Response To Sildenafil Therapy For Pulmonary Arterial Hypertension Is Associated With Long Term Outcome
  25. Parental assessment of adolescent quality of life: can it replace self-assessment?
  26. Risk and Cumulative Risk of Stroke Recurrence: A Systematic Review and Meta-Analysis
  27. Cluster randomised trial in the General Practice Research Database: 1. Electronic decision support to reduce antibiotic prescribing in primary care (eCRT study)
  28. Potential application of item-response theory to interpretation of medical codes in electronic patient records
  29. Cluster Randomized Controlled Trial of a Patient and General Practitioner Intervention to Improve the Management of Multiple Risk Factors After Stroke: Stop Stroke
  30. Entwicklung der deutschen Version der Patientenzufriedenheits-Skala (SASC) für den Einsatz bei Patienten nach Schlaganfall
  31. Frequency and predictors for the risk of stroke recurrence up to 10 years after stroke: the South London Stroke Register
  32. Nurse delivered endoscopy
  33. Black and minority ethnic men who have sex with men: a London genitourinary medicine clinic experience
  34. Ethnic Group Disparities in 10-Year Trends in Stroke Incidence and Vascular Risk Factors: The South London Stroke Register (SLSR)
  35. European regulatory agencies should employ full time statisticians
  36. Flexible Design and Efficient Implementation of Adaptive Dose-Finding Studies
  37. Discussion of the “White Paper of the PhRMA Working Group on Adaptive Dose-Ranging Designs”
  38. Adaptive Designs in Clinical Drug Development: Opportunities, Challenges, and Scope Reflections Following PhRMA's November 2006 Workshop
  39. Simulation-based sequential Bayesian design
  40. Statistical issues in first-in-man studies
  41. 25 years of Bayesian methods in the pharmaceutical industry: a personal, statistical bummel
  42. The association of post-stroke neurological improvement with risk of subsequent deterioration due to stroke events
  43. A Bayesian Decision-Theoretic Dose-Finding Trial
  44. Guest Editors' Note for the Special Issue on “Design and Analysis of Dose-Response Clinical Trials”
  45. Implementation of a Bayesian adaptive design in a proof of concept study
  46. The professionalization of the 'shoe clerk'
  47. ASTIN: a Bayesian adaptive dose–response trial in acute stroke
  48. Career story: Pharmaceutical Statistician
  49. Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): An Adaptive Dose-Response Study of UK-279,276 in Acute Ischemic Stroke
  50. The number needed to treat: a useful clinical measure or a case of the Emperor's new clothes?
  51. Do statisticians count? A personal view
  52. Adaptive Bayesian Designs for Dose-Ranging Drug Trials
  53. A Comment on Optimal Allocations for Bioequivalence Studies
  54. Issues for statisticians in pharmaco-economic evaluations
  55. Issues for statisticians in pharmaco‐economic evaluations
  56. Bayesian and frequentist approaches to the cross-over trial
  57. Joint equivalence of means and variances of two populations
  58. A Comment on Interim Analyses in Crossover Trials
  59. Extending a Bayesian Analysis of the Two-Period Crossover to Accommodate Missing Data
  60. Extending a Bayesian analysis of the two-period crossover to accommodate missing data
  61. A Further Note on Sampling to Locate Rare Defectives with Strong Prior Evidence
  62. Bayesian analyses of two-treatment crossover studies
  63. Crossover studies
  64. Extending a Bayesian analysis of the two-period crossover to allow for baseline measurements
  65. Statistical Methods in Analytical Chemistry.
  66. A further note on sampling to locate rare defectives with strong prior evidence
  67. Cross-Over Trials in Clinical Research.
  68. Measuring Your Posterior Beliefs That you can Count Properly
  69. Design and analysis of bioavailability and bioequivalence studies. Shein-Chung Chow and Jen-Pei Liu, Marcel Dekker, New York, 1992. No. of pages: x + 416. Price: $125. ISBN 0-8247-8682-3
  70. Confidence Intervals on Variance Components.
  71. `Student'-A Statistical Biography of William Sealy Gosset: Based on the Writings of E. S. Pearson.
  72. Confidence Intervals and Sample Sizes
  73. On the construction of shortest confidence intervals and Bayesian highest posterior density intervals
  74. Predictive Probability in Clinical Trials
  75. A further note on some wishart expectations
  76. A Quasirandom Approach to Integration in Bayesian Statistics
  77. A Two-Stage Procedure for Bioequivalence Studies
  78. Discussion of Piegorsch and Gladen (1986)
  79. A Note on the Analysis of the Two-Period Crossover Design When the Period-Treatment Interaction is Significant
  80. Applications of Bayesian Software: Two Examples
  81. Bayesian Methods in Practice: Experiences in the Pharmaceutical Industry
  82. The role of Schmidt-Lanterman incisures in Wallerian degeneration
  83. A Bayesian Analysis of the Two-Period Crossover Design for Clinical Trials
  84. A non-parametric confidence interval method
  85. Seasonal variation of temperatures in rabbits
  86. Tests of sphericity of normal distributions and the analysis of repeated measures designs
  87. Fully automated and fast image analysis of autoradiographs with a TAS-Leitz. Determination of size, Feulgen fluorescence and grain counts of individual nuclei and their evaluation by a simplified cluster analysis
  88. Bayesian Approach to Bioequivalence Assessment: An Example
  89. Pharmacokinetic and pharmacodynamic studies of single oral doses of metoprolol in normal volunteers
  90. Medical Statistics
  91. Medical Statistics